India’s Pharma Exports in FY25 Cross $30 Billion Mark

India’s pharmaceutical industry has achieved a significant milestone in FY25, with drug and pharma exports crossing the $30 billion mark for the first time ever. The impressive 31% year-on-year surge in March 2025 played a pivotal role in surpassing the annual target of $29.38 billion. This growth came amid several global challenges, including geopolitical tensions and threats of U.S. tariffs, which fortunately did not affect pharma exports. The United States remained India’s top export destination, while other key markets like the UK, Brazil, and France contributed modestly. Key product categories like drug formulations and biologicals led the surge, while some regions such as Africa and Northeast Asia saw slight declines.

Key Highlights

FY25 Total Pharma Exports

• Touched $30.47 billion, up 9.39% from $27.85 billion in FY24.
• Exceeded the FY25 target of $29.38 billion.

March 2025 Surge

• Exports rose 31.21% YoY, reaching $3.68 billion.
• One of the strongest monthly performances of the fiscal year.

Top Performing Months

• January 2025: 21.47% growth
• May 2024: 10.63% growth
• February 2025: Only month with a contraction (-1.52%)

Product Categories (April–Feb FY25)

• Drug formulations & biologicals: $20.12 billion (75%+ share, 9% growth)
• Bulk drugs & intermediates: $4.31 billion (1.40% growth)
• Vaccines: $1.04 billion (down 4.20%)
• Surgical products: $683.47 million (up 5.16%)
• Ayush & herbal products: $620.97 million (up 6.17%)

Top Markets

• United States: $8.95 billion (14.29% growth, 1/3rd of total exports)
• Others: UK, Brazil, France, South Africa (combined <10.5%)

Markets with Export Decline

• UAE (-17.7%), Turkey (-16%), Sri Lanka (-14.6%),
• Netherlands (-13.79%), China (-10.6%), Belgium (-7.37%)

Regional Export Share

• NAFTA (incl. U.S.): 36.6% share, 14.06% growth to $9.8 billion
• Europe, Africa, and LAC: Major contributors
• Africa saw a decline of 1.74%, as did North-East Asia

U.S. Tariff Threats

• A proposed 26% tariff on goods by President Trump spurred export rush
• Pharma products excluded from tariff list

Summary/Static	Details
Why in the news?	India’s Pharma Exports in FY25 Cross $30 Billion Mark
Total Pharma Exports (FY25)	$30.47 billion
Total Pharma Exports (FY24)	$27.85 billion
Growth in Total Exports (YoY)	9.39%
Target for FY25	$29.38 billion
March 2025 Exports	$3.68 billion
Growth in March 2025 (YoY)	31.21%
Top Export Destination	United States
U.S. Exports Value (FY25)	$8.95 billion
Growth in U.S. Exports (YoY)	14.29%
Drug Formulations & Biologicals	$20.12 billion (+9% YoY)
Bulk Drugs & Intermediates	$4.31 billion (+1.40% YoY)
Vaccine Exports	$1.04 billion (−4.20% YoY)
Surgical Products Exports	$683.47 million (+5.16% YoY)
Ayush & Herbal Products	$620.97 million (+6.17% YoY)
Region with Highest Share	NAFTA (36.6% share)
NAFTA Export Value	$9.80 billion (+14.06% YoY)
Regions with Decline	Africa (−1.74%), N.E. Asia
Countries with Declining Exports	UAE, Turkey, Sri Lanka, China, etc.
U.S. Tariff Impact on Pharma	Exempted from 26% tariff threat
Tariff Status	On hold for 90 days